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Western Pacific amyotrophic lat-eral sclerosis (ALS) and parkin-
sonism-dementia complex (PDC), a 
prototypical neurodegenerative disease 
(polyproteinopathy) affecting distinct 
genetic groups with common expo-
sure to neurotoxic chemicals in cycad 
seed, has many features of Parkinson 
and Alzheimer diseases (AD), includ-
ing early olfactory dysfunction. Guam 
ALS-PDC incidence correlates with 
cycad flour content of cycasin and its 
aglycone methylazoxymethanol (MAM), 
which produces persistent DNA damage 
(O6-methylguanine) in the brains of mice 
lacking O6-methylguanine methyltrans-
ferase (Mgmt-/-). We showed in Mgmt-/- 
mice up to 7 d post-MAM treatment 
that brain DNA damage was linked to 
brain gene expression changes found in 
human neurological disease, cancer and 
skin and hair development. This adden-
dum reports 6 mo post-MAM treatment-
related brain transcriptional changes 
as well as elevated mitogen activated 
protein kinases and increased caspase-3 
activity, both of which are involved 
in tau aggregation and neurofibrillary 
tangle formation typical of ALS-PDC 
and AD, plus transcriptional changes in 
olfactory receptors. Does cycasin act as a 
“slow (geno)toxin” in ALS-PDC?
We showed that methylazoxymethanol 
(MAM), the genotoxic metabolite of the 
cycad plant carcinogen cycasin (MAM-
β-d-glucoside), induced in young adult 
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mice lacking O6-methylguanine (O6-mG) 
methyltransferase (Mgmt-/-)—the enzyme 
that repairs O6-mG DNA lesions—
a O6-mG-linked brain transcriptional 
response associated with human neuro-
logical disease.1 This supports an etiologic 
role for the azoxyglycoside cycasin in the 
genesis of a disappearing degenerative 
brain disease (amyotrophic lateral sclero-
sis and parkinsonism-dementia complex, 
ALS-PDC) found among the genetically 
distinct island populations of Guam and 
Rota (Chamorros), Honshu (Japanese) 
and New Guinea (Papuan New Guinean), 
which used cycad seed as medicine applied 
orally (Kii Peninsula, Honshu) or topi-
cally (West Papua), or for both topical 
medicine and food (Guam and Rota). In 
all three disease foci, periods of years or 
decades intervene between exposure to 
cycad seed and the development of ALS-
PDC, suggesting the operation of a “slow 
toxin” able to trigger a progressive neuro-
nal disease reminiscent of look-a-like dis-
orders of old age (e.g., Alzheimer disease, 
AD) elsewhere in the world.2 Both AD and 
ALS-PDC have neurofibrillary tangles 
containing the microtubule tau protein in 
a hyperphosphorylated state,3-5 which has 
been linked to both activation of serine-
threonine kinases (Erk-1/2, p38, c-Jun 
NH
2
-terminal kinase) in the mitogen-
activated protein kinase (MAPK) pathway 
and to phosphorylation of the C-terminal 
fragment of amyloid precursor protein 
(APP).6 More recent studies suggest the 
activation of non-apoptotic caspases may 
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perturbed in MAM
late
 Mgmt-/- mice were 
identified by integrating the transcripts 
with their gene products and overlaying 
these with known molecular interactions 
using IngenuityTM Pathway Analysis (IPA, 
Redwood City, CA). The three top-ranked 
IPA Biofunction Diseases and Disorders 
included: inflammatory response, cancer 
and genetic disorders. We identified 355 
genes that were differentially expressed 
between the brains of MAM
late
- and 
vehicle-treated Mgmt-/- mice. IPA analysis 
retained 85% of these genes (302 of the 
355) in the construction of 176 networks. 
The three top-scoring IPA networks 
contained 23 (#1), 25 (#2) and 21 (#3) 
focus molecules, including hubs for Akt, 
transforming growth factor β (Tgfβ) and 
histone h3 (#1), calcineurin and nuclear 
factor kappa-light-chain-enhancer of acti-
vated B cells (NFκB complex) (#2) and 
Erk1/2, MAPK and collagen(s) (#3). 
The most significant Kyoto Encyclopedia 
of Genes and Genomes (KEGG) path-
ways were determined with DAVID (the 
Database for Annotation, Visualization 
and Integrated Discovery) bioinformat-
ics software. Based on 291 genes, DAVID 
identified six pathways (n = 4 or more 
genes per pathway) common to MAM
early
 
and MAM
late
 and three unique to MAM
late
 
(Table 1): the latter included genes cod-
ing for olfactory receptors that were both 
upregulated (n = 25) and downregu-
lated (n = 3). Parkinson disease was one 
of 23 additional KEGG pathways (n = 2 
or 3 genes per pathway). Brain KEGG 
pathways common to both MAM
late
 and 
MAM
early
 animals included: Pathways in 
Cancer, MAPK, Focal Adhesion Pathway, 
Neuroactive Receptor Interaction 
Pathway, Steroid Hormone Biosynthesis 
and the Calcium Signaling Pathway 
(Table 1). The MAPK signaling pathway 
involved 3 upregulated genes [activin A 
receptor, type 1B (Acvr1b)], a member of 
the transforming-growth factorβ family 
linked to skin epithelial cell proliferation 
and hair development,10 calcium chan-
nel voltage-dependent α2/delta subunit 4; 
serine/threonine kinase-3) (CACNA2D3), 
a neuroblastoma marker gene,11 and 1 
downregulated gene, raffinose permease 
(RafB), a MAPK protein pathway gene.12
The left half of each brain was analyzed 
by protein gel blotting for components of 
n = 4) or a comparable volume of vehicle 
consisting of 0.5% acetic acid in saline 
(n = 3). Animals were housed singly, fed 
rodent chow ad libitum for 6 mo, during 
which all animals grew and maintained 
apparent health, and then decapitated by 
guillotine.
The right half of the MAM
late
 brain 
was employed for gene expression analysis 
using mouse oligo microarrays (~21,000 
features) by Agilent (Santa Clara, CA). 
As in the previously published MAM
early
 
study,1 brain cellular networks putatively 
be one of the earliest events that triggers 
tau aggregation and the accumulation of 
neurofibrillary tangles in tauopathies.7-9 
Here, we supplement data on the short-
term actions (up to 7 d) of MAM on brain 
gene expression in O6-mG-deficient mice 
(MAM
early
) with preliminary findings on 
caspase activity and the transcription and 
protein expression of brain cell signaling 
proteins 6 mo post-treatment (MAM
late
).
Seven 11-week-old male Mgmt-/- mice 
were treated with a single intraperitoneal 
dose of MAM (20 mg/kg body weight, 
Table 1. KeGG pathways from DaVID based on 407/443 (DaVID recognized/submitted) 
KEGG Pathway MAMearly MAMlate
Pathways in cancer 13 4
Insulin signaling pathway 9
Wnt signaling pathway 10
Purine metabolism 9
maPK signaling pathway 7 4
Prostate cancer 8
acute myeloid leukemia 5
Chronic myeloid leukemia 5
Neurotrophin signaling pathway 6
Huntington’s disease 5
Focal adhesion 6 4
Neuroactive ligand-receptor interaction 5 4
Nucleotide excision repair 4
Steroid hormone biosynthesis 4 4
endometrial cancer 5
Glioma 4
Long-term potentiation 4
Long-term depression 5
Small cell lung cancer 4
Colorectal cancer 5
apoptosis 4
erbB signaling pathway 5
melanogenesis 6
axon guidance 5
Calcium signaling pathway 4 4
endocytosis 4
regulation of actin cytoskeleton 5
Chemokine signaling pathway 5 4
Basal cell carcinoma 4
alzheimer disease 4
Olfactory transduction 28
eCm-receptor interaction 5
Cytokine-cytokine receptor interaction 5
affymetrix probe IDs (mamearly) or 291/355 GeNBaNK accession numbers (mamlate). Both sets 
restricted to pathways containing at least four probes/genes.
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the MAPK (perturbed in both MAM
late
 
and MAM
early
) and phosphatidylinosi-
tol-3-kinase/Akt (PI3K/Akt) signaling 
pathways and activity of caspase-3 (the 
APP cleavage protein linked to AD).8,9 In 
MAM
late
, significant increases were found 
in Erk-1 (p < 0.03) and fodrin cleavage 
(p < 0.01) (Fig. 1). Brain fodrin cleavage, 
which was increased in MAM
late
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indicates the activation of caspase-3, an 
enzyme with an important role in cleaving 
tau.14 MAM
late
 transcriptional changes in 
extracellular-matrix-receptor interaction 
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late
 transcriptional profile 
was dominated by the presence of 28 (of 
a total of ~1,300) genes involved in olfac-
tory transduction,16 including chloride 
channel activated 6, which suggest the 
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olfaction status. While caution is mer-
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mon neurologic substrate and underlines 
the close relationship between ALS-PDC 
and the more familiar neurodegenerative 
disorders seen in the West.
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Figure 1. effect of mamlate on components of the maPK signaling pathway and caspase activ-
ity. the left half brains of vehicle- (n = 3) and mam- (n = 4) treated Mgmt-/- mice were flash frozen 
in liquid N2, the frozen tissue subjected to ultrasonication in gel electrophoresis buffer to avoid 
loss of protein modifications or lysis, and the homogenate heat-denatured at 95°C for 5 min. an 
aliquot of the brain tissue homogenate (50 μg) was resolved on a 10% polyacrylamide gel, trans-
ferred to PVDF membranes, the blocked membranes probed with monoclonal antibodies to erK 
(erK1, erK2), phosphorylated erK (perK1, perK2), PI3K (p110γ) (Santa Cruz Biotechnology, Inc.,) 
and α-fodrin (Chemicon), and the bands visualized by chemiluminescence detection. α-Fodrin 
cleavage was determined using the 120 kDa band. membranes were scanned on a microtek 
flatbed scanner and each band quantified using molecular analyst software (Biorad, Inc.), with 
background subtraction as described previously in reference 13. Values are the mean ± standard 
error. Significantly different from vehicle (*p < 0.03 or **p < 0.01 by aNOVa).
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